Skip to main content
. 2020 Jun 12;16(12):3184–3193. doi: 10.1080/21645515.2020.1754691

Figure 3.

Figure 3.

A combination of TMV vaccine and anti-CTLA-4 mAb enhances the survival of mice after resection of primary tumor. (a) Tumor challenge/resection and immunotherapy protocol design. (b) Kaplan-Meier survival curves of control and anti-CTLA-4 mAb treated groups. Comparison of TMV vaccine + anti-CTLA-4 mAb and anti-CTLA-4 mAb alone yields p = .0074, n = 5–10. Comparison of TMV vaccine + anti-CTLA-4 mAb and TMV vaccine + Mouse IgG yields p = .0105, n = 5–10. Log-rank (Mantel-Cox) test used for comparison analysis. (c) Kaplan-Meier survival curves of control and anti-PD-L1 mAb treated groups. **p ≤ 0.01.